^
    Contact us  to learn more about
    our Premium Content:  News alerts, weekly reports and conference planners
    DRUG CLASS:

    CD19-targeted CAR-T immunotherapy

    Related drugs:
    16h
    Atalanta-1: A Study Evaluating the Safety and Efficacy of GLPG5101 (19CP02) in Participants With Non-Hodgkin Lymphoma (clinicaltrials.gov)
    P1/2, N=274, Active, not recruiting, Galapagos NV | Recruiting --> Active, not recruiting
    Enrollment closed
    18h
    Anti-CD19 Chimeric Antigen Receptor T-Cell Immunotherapy for Chronic Lymphocytic Leukemia (CLL) (clinicaltrials.gov)
    P1/2, N=66, Recruiting, National Cancer Institute (NCI) | N=132 --> 66
    Enrollment change
    |
    CD19 (CD19 Molecule)
    |
    Rituxan (rituximab) • cyclophosphamide • fludarabine IV
    1d
    Case Report: CD19 CAR-T therapy induces durable remission in a pediatric patient with TP53-mutated, refractory Burkitt lymphoma: a 30-month follow-up. (PubMed, Front Oncol)
    This case, among the youngest reported uses of commercial Axi-cel for BL, highlights the diagnostic complexity in adolescent lymphoma and demonstrates that CD19 CAR-T therapy can overcome TP53-associated chemoresistance in adolescent BL. It also suggests that integrating molecular profiling and immunotherapy may provide new strategies for managing high-risk, treatment-refractory cases in the adolescent and young adult population.
    Journal • IO biomarker
    |
    TP53 (Tumor protein P53)
    |
    TP53 mutation
    |
    Yescarta (axicabtagene ciloleucel)
    1d
    REFUEL: A Second Infusion (Early Reinfusion) of Tisagenlecleucel in Children and Young Adults With B-Cell Acute Lymphoblastic Leukemia(B-ALL) (clinicaltrials.gov)
    P2, N=30, Active, not recruiting, Memorial Sloan Kettering Cancer Center | Trial completion date: Jul 2026 --> Jul 2027 | Trial primary completion date: Jul 2026 --> Jul 2027
    Trial completion date • Trial primary completion date
    |
    CD19 (CD19 Molecule) • IFNG (Interferon, gamma)
    |
    Kymriah (tisagenlecleucel-T)
    2d
    BHCT-RD06-04-01: Anti-CD19 CAR-T Cell Therapy in Participants With Moderate to Severe Active Systemic Lupus Erythematosus (clinicaltrials.gov)
    P=N/A, N=12, Suspended, Union Hospital, Tongji Medical College, Huazhong University of Science and Technology | Recruiting --> Suspended | Trial primary completion date: Mar 2025 --> Dec 2026
    Trial suspension • Trial primary completion date
    3d
    BHCT-RD06-04-04: A Study of RD06-04 in Patients With Active Autoimmune Diseases (clinicaltrials.gov)
    P1, N=0, Withdrawn, Nanjing Bioheng Biotech Co., Ltd. | N=18 --> 0 | Not yet recruiting --> Withdrawn
    Enrollment change • Trial withdrawal
    |
    LRP4 (LDL Receptor Related Protein 4)
    3d
    BHCT-RD06-04-05: Clinical Study on Targeted CD19CAR-T Therapy for Autoimmune Diseases (clinicaltrials.gov)
    P1, N=12, Suspended, Nanjing Bioheng Biotech Co., Ltd. | Recruiting --> Suspended
    Trial suspension
    |
    cyclophosphamide • fludarabine IV
    4d
    CS22-03: Observational Study of People Living With HIV Treated With CD19-directed CAR T Cell (clinicaltrials.gov)
    P=N/A, N=30, Completed, AIDS Malignancy Consortium | Active, not recruiting --> Completed
    Trial completion
    4d
    PBCAR0191-01: Dose-escalation and Dose-expansion Study of Safety of Azer-cel (PBCAR0191) in Participants With Relapsed/Refractory (r/r) Non-Hodgkin Lymphoma (NHL) and r/r B-cell Acute Lymphoblastic Leukemia (B-ALL) (clinicaltrials.gov)
    P1, N=135, Recruiting, Imugene Limited | Trial primary completion date: Jun 2025 --> Jun 2027
    Trial primary completion date
    |
    cyclophosphamide • fludarabine IV • azercabtagene zapreleucel (PBCAR0191)
    4d
    ZUMA-24: Study of Axicabtagene Ciloleucel Given With Steroids In Participants With Relapsed Or Refractory Large B-Cell Lymphoma (clinicaltrials.gov)
    P2, N=35, Completed, Kite, A Gilead Company | Active, not recruiting --> Completed
    Trial completion
    |
    BCL2 (B-cell CLL/lymphoma 2) • BCL6 (B-cell CLL/lymphoma 6) • CXCL8 (Chemokine (C-X-C motif) ligand 8) • CSF2 (Colony stimulating factor 2) • IL15 (Interleukin 15) • IL1R1 (Interleukin 1 receptor, type I) • IL7 (Interleukin 7)
    |
    cyclophosphamide • Yescarta (axicabtagene ciloleucel) • fludarabine IV
    4d
    Testing Drug Treatments After CAR T-cell Therapy in Patients With Relapsed/Refractory Diffuse Large B-cell Lymphoma (clinicaltrials.gov)
    P2, N=396, Recruiting, SWOG Cancer Research Network | Trial completion date: Dec 2029 --> Jun 2030 | Trial primary completion date: Dec 2025 --> Jun 2030
    Trial completion date • Trial primary completion date
    |
    cyclophosphamide • Yescarta (axicabtagene ciloleucel) • Breyanzi (lisocabtagene maraleucel) • Kymriah (tisagenlecleucel-T) • fludarabine IV • Polivy (polatuzumab vedotin-piiq) • Lunsumio (mosunetuzumab-axgb)
    5d
    Lythesia: A Non-Interventional Study PASS to Characterize Secondary Malignancies of Tcell Origin Following Tisagenlecleucel Therapy (clinicaltrials.gov)
    P=N/A, N=30, Not yet recruiting, Novartis Pharmaceuticals
    New trial
    |
    Kymriah (tisagenlecleucel-T)